08622 HUAKANG BIOMED
- 0.121
- -0.015-11.03%
HUAKANG BIOMED News
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Huakang Biomed (08622): Xu Ming has been appointed as a non-executive director.
huakang biomed (08622) announced that Xu Ming has been appointed as a non-executive director of the company, effective from October 2024...
HUAKANG BIOMED: 2024 INTERIM REPORT
Huakang Biomed (08622) announced its interim results, with a net loss of approximately 1.779 million yuan attributable to owners, a 22.27% year-on-year increase in the loss.
Huakang Biomed (08622) announced its 2024 interim performance, with revenue increasing by about 4% YoY to 11.9 million yuan...
HUAKANG BIOMED: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
HK stocks surge | Huakang Biomedical (08622) rose more than 40% in mid-day trading, planning to carry out online store and enzyme-based product trade business.
Huakang Biomedical (08622) rose more than 40% in intraday trading. As of press time, it has risen 31.63%, with a share price of HKD 0.129 and a turnover of HKD 0.401 million.
Huakang Biomed (08622.HK) plans to carry out enzyme-based product trade business involving online sales platforms and corporate-to-corporate trade operations of Enzyme Good Life Group (China) Co., Ltd.
On July 22, Gelonhui announced that Huakang Biomedical (08622.HK) plans to conduct enzyme-based product trading business ("new business activities") related to online sales platforms and enterprise-to-enterprise products for Haosheng Group (China) Co., Ltd. which is primarily engaged in the research and development, production, marketing and sales of in vitro diagnostic reagents, assisted reproductive supplies and equipment in China. The board of directors is actively exploring new business opportunities to bring higher returns to shareholders. Considering the sustained growth potential of enzyme-based products and e-commerce consumption in the domestic market in China in recent years, the directors believe that the implementation of new business activities will bring more opportunities for the group.
Huakang Biomed (08622) is carrying out new business activities.
Huakang Biomed (08622) announced that the group plans to conduct activities related to online sales platforms and enterprise-to-enterprise product trade...
Express News | Huakang Biomedical - Intends to Commence Trading Business of Enzyme- Based Products of Bestyzym + Bestlife Group (China)
HUAKANG BIOMED: DISCLOSEABLE TRANSACTION AND ADVANCE TO ENTITY REPAYMENT ARRANGEMENT IN RELATION TO ACQUISITION OF 19% EQUITY INTEREST OF THE TARGET COMPANY AND PROVISION OF LOAN
HUAKANG BIOMED: ANNUAL REPORT 2023
Huakang Biomedical (08622) completed placement of 31 million shares to raise approximately HK$2.96 million
Huakang Biomedical (08622) issued an announcement. The conditions for the placement have been met, and on April 2, 2024...
Huakang Biomedical (08622.HK): Chen Jiansheng Resigns as Independent Non-Executive Director
Huakang Biomedical (08622.HK) announced that Chen Jiansheng resigned as an independent non-executive director of the company, a member of the Audit Committee and Nomination Committee in order to invest more time in his personal business and other matters, effective April 2, 2024.
HUAKANG BIOMED: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2023
Huakang Biomedical (08622) Fa Ying Guang expects annual shareholders' losses to be no more than 5.8 million yuan
Huakang Biomedical (08622) issued an announcement that it is expected that the company owner's losses during the period will end in December 2023...
HUAKANG BIOMED: PROFIT WARNING
Huakang Biomedical (08622) completed the placement of a total of 31 million shares to raise approximately HK$3.18 million
Huakang Biomedical (08622) issued an announcement. The conditions for the placement have been met, and on March 2, 2024...
Huakang Biomedical (08622) has signed a memorandum of understanding with respect to potential sales and distribution cooperation in China
According to Zhitong Finance App News, Huakang Biomedical (08622) announced that Huakang Hong Kong, a direct wholly-owned subsidiary of the company, signed a memorandum of understanding with Fujig after the trading session on February 20, 2024. The details include potential sales and distribution cooperation in China (including) selling and distributing the company's biological agents and immediate biomedical testing products on the platforms and channels of Fujig in China. Other than a few provisions (including due diligence, validity and exclusivity, confidentiality, and applicable law and jurisdiction), the MOU is not legally binding. The directors believe that if cooperation with pig saving is implemented, it will be
No Data